This collaboration with Cambridge based Wren Therapeutics follows similar announcements earlier this year from the UK External Innovation team at Eisai’s Hatfield Research Laboratories, as it continues to explore partnerships and opportunities to further innovate in the lifesciences sector.

Both companies have entered into this exclusive research collaboration with the aim of advancing the discovery of novel small molecules that target a-synuclein for the potential treatment of conditions such as Parkinson’s disease and dementia with Lewy bodies.

These neurodegenerative conditions represent a significant unmet medical need due to the lack of any effective disease-modifying treatments and it is hoped that by integrating capabilities across both companies, the development of potential clinical candidates can be accelerated.

This agreement will use the extensive experience in drug discovery for neurodegenerative disorders from the UK External Innovation team at Eisai’s Hatfield Research Laboratories alongside Cambridge based Wren Therapeutics network kinetics drug discovery platform.

Post Navigation